Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filipa Lynce

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancerFilipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Breast Cancer Research : BCR|September 30, 2025
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II studyKristina Fanucci, Eren D Yeh, Ruichao Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2021
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBCSagar D Sardesai, Alexandra Thomas, Christopher Gallagher, et al.
Breast Cancer Research and Treatment|August 2, 2025
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective studyToshiaki Iwase, Nithya Sridhar, Megumi Kai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology GuidelineIsabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesTam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
JAMA Oncology|June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerShaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, et al.
Breast Cancer Research and Treatment|December 28, 2023
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancerFaina Nakhlis, Samuel M Niman, Naoto T Ueno, et al.
Cancer|May 14, 2026
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025Eleonora Nicolò, François Bertucci, Hamouda Boussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced MalignanciesNehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2025
A phase Ib study of sapacitabine and olaparib in patients with BRCA1/2-mutated metastatic breast cancerFilipa Lynce, Noah Graham, Bose S Kochupurakkal, et al.
Breast Cancer Research : BCR|September 30, 2025
Neoadjuvant therapy with eribulin, doxorubicin and cyclophosphamide for patients with HER2-negative inflammatory breast cancer: a phase II studyKristina Fanucci, Eren D Yeh, Ruichao Shi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 17, 2021
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBCSagar D Sardesai, Alexandra Thomas, Christopher Gallagher, et al.
Breast Cancer Research and Treatment|August 2, 2025
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective studyToshiaki Iwase, Nithya Sridhar, Megumi Kai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology GuidelineIsabelle Bedrosian, Mark R Somerfield, Maria Isabel Achatz, et al.
Biorxiv : the Preprint Server for Biology|September 5, 2025
Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesTam Binh V Bui, Denise M Wolf, Michael C Bruck, et al.
JAMA Oncology|June 14, 2019
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast CancerShaveta Vinayak, Sara M Tolaney, Lee Schwartzberg, et al.
Breast Cancer Research and Treatment|December 28, 2023
Clinical outcomes after 1 versus 2-3 lines of neoadjuvant therapy in stage III inflammatory breast cancerFaina Nakhlis, Samuel M Niman, Naoto T Ueno, et al.
Cancer|May 14, 2026
Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025Eleonora Nicolò, François Bertucci, Hamouda Boussen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2024
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced MalignanciesNehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, et al.
Pageof 10